1 completed, 1 recruiting, 1 suspended. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Suspended 1 |
| Phase 1 | 1 | Completed 1 |
Follow Magtrace: new trials by email Literature Review of Magtrace trials Research Report on Magtrace
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) Magtrace - Ductal Carcinoma in Situ | Phase 2 | Suspended | University of Florida | 30 | 2026-10-01 | 2026-09-11 |
| Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients Superparamagnetic Iron Oxide, Technetium99 - Breast Cancer, Sentinel Lymph Node | Phase 2 | Recruiting | Vastra Gotaland Region | 220 | 2023-01-01 | 2024-01-26 |
| Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide Superparamagnetic Iron Oxide - Breast Cancer, Sentinel Lymph Node | Phase 1 / Phase 2 | Completed | Vastra Gotaland Region | 50 | 2021-11-01 | 2025-03-28 |
Breast Neoplasms (2) · Carcinoma, Intraductal, Noninfiltrating (1) · Lymphedema (1)
Vastra Gotaland Region (2) · University of Florida (1)
Sweden (2) · United States (1)